AFT appoints Allison Yorston as independent director
AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com
12 November 2024
AFT appoints Allison Yorston as independent
director
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces the appointment of
Allison Yorston as an independent non-executive director.
The appointment fills the vacancy left by Anita Baldauf who retired from the board at
the shareholders meeting in August.
Chair David Flacks says: “We are delighted to welcome Allison to our board. She has
outstanding experience as a senior marketing executive in Australia and New Zealand
and is currently the Chief Marketing Officer for Suntory Beverage and Food Oceania.
“Allison’s senior marketing experience is highly relevant to AFT as we grow and
consolidate our position in Australasia and build our presence internationally with our
Maxigesic® pain relief and other medications.”
Allison says: “I am excited by the opportunity to assist AFT with its growth aspirations
and honoured to join the experienced board. I look forward to utilising my strategic,
commercial and marketing skillset for positive impact.”
The board has determined that Allison Yorston is an Independent Director (within the
meaning of the NZX Listing Rules).
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals
AFT is a growing New Zealand based multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter (OTC), prescription and
hospital. Our product portfolio comprises both proprietary and in-licensed products,
AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com
and includes patented, branded, and generic drugs
1
. Our business model is to
develop and in-license products for in our markets of Australia, New Zealand,
Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-
license our products to local licensees and distributors to over 125 countries around
the world. For more information about the company, visit our website
www.aftpharm.com.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- ATM — The a2 Milk Company Limited: Appointment of new independent NED – Lain Jager2024-11-17
“NZX Code: ATM ASX Code: A2M The a2 Milk Company Limited www.thea2milkcompany.com 18 November 2024 NZX/ASX Market Release Appointment of new independent NED – Lain Jager The a2 Milk Company (a2MC, the Company) advises that Lain Jager has been appointed as an independe…”